Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Nov 16, 2022

BUY
$58.04 - $100.2 $178,473 - $308,115
3,075 New
3,075 $220,000
Q2 2022

Aug 15, 2022

BUY
$58.04 - $100.2 $178,473 - $308,115
3,075 New
3,075 $220,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.9B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Brookfield Asset Management Inc. Portfolio

Follow Brookfield Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brookfield Asset Management Inc. with notifications on news.